About
Team
Pipeline
OPN-2853
OPN-7486
OPN-6602
OPN-9627
OPN-9840
OPN-FMRP
Patients
News
Press Releases
Publications
& Posters
Careers
Contact
General information
info@opnabio.com
Investor inquiries
bd@opnabio.com
Media and BD inquiries
bd@opnabio.com
2018
Select PROGRAMS
All Programs
OPN-2853
(8)
OPN-51107
(17)
OPN-6602
(1)
OPN-7486
(5)
Select Dates
All Dates
2023
(3)
2022
(1)
2021
(3)
2020
(3)
2019
(7)
2018
(4)
2017
(3)
2016
(2)
2015
(3)
August 23, 2018
Publication
ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition
AUTHORS
Roberts, et al
Programs
OPN-7486
https://doi.org/10.1182/blood-2018-05-849554
June 6, 2018
Publication
Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the antitumor efficacy of immune checkpoint blockade
AUTHORS
Duffy, et al
Programs
OPN-7486
https://www.jimmunol.org/content/200/1_Supplement/122.15/tab-article-info
May 20, 2018
Poster
Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors
AUTHORS
Patnaik, et al
Programs
OPN-2853
Download PDF
January 31, 2018
Publication
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
AUTHORS
Ozer , et al
Programs
OPN-51107
https://doi.org/10.1158/2159-8290.CD-17-0902